22:45 , Jun 20, 2018 |  BC Extra  |  Company News

Management tracks: Sanofi, NantKwest

Sanofi (Euronext:SAN; NYSE:SNY) hired Jean-Baptiste Chasseloup de Chatillon as EVP and CFO, effective Oct. 1. He was CFO and EVP at automotive company PSA Group (Euronext:UG). Natural killer cell company NantKwest Inc. (NASDAQ:NK) said Chief...
23:33 , Oct 6, 2017 |  BC Extra  |  Company News

Management tracks: Impel, InGeneron

Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) named Jon Congleton president and CEO. He was president and CEO at Nivalis Therapeutics Inc. , which merged with Alpine Immune Sciences Inc. (NASDAQ:ALPN). Regenerative medicine company...
21:32 , Sep 29, 2017 |  BC Week In Review  |  Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
23:18 , Sep 25, 2017 |  BC Extra  |  Company News

Aegerion to pay fine for Juxtapid violations

Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as...
00:38 , Apr 1, 2017 |  BC Extra  |  Company News

Management tracks

Immuno-oncology company Forty Seven Inc. (Palo Alto, Calif.) named Mark McCamish CEO, effective May 1. He was global head of biopharmaceutical development at the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). Founding CEO Jonathan MacQuitty...
17:15 , Dec 9, 2016 |  BC Week In Review  |  Company News

Amryt, Aegerion deal

Aegerion granted Amryt exclusive rights to market Lojuxta lomitapide in the European Economic Area (EEA), Middle East and North Africa (MENA), Israel and Turkey. Aegerion is eligible for milestone payments, plus royalties. Amryt will be...
00:06 , Dec 3, 2016 |  BC Extra  |  Company News

Management tracks

Prescription and OTC pharma Taro Pharmaceutical Industries Ltd. (NYSE:TARO) said Uday Baldota will replace Kal Sundaram as its CEO, effective April 2017. Baldota is EVP and CFO at Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA). Abhay...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Juxtapid regulatory update

Aegerion said Japan approved Juxtapid lomitapide to treat patients with homozygous familial hypercholesterolemia (HoFH). The product is a small molecule microsomal triglyceride transfer protein ( MTTP ; MTP) inhibitor and is approved in the U.S....
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...